Navigation Links
TB, HIV and malaria vaccine research gets major boost
Date:5/7/2013

Rockville, MD, US, Oxford, UK and Basel, Switzerland 7 May 2013 Aeras, a nonprofit biotech advancing TB vaccines for the world, the University of Oxford and Okairos, a biopharmaceutical company specializing in T-cell vaccines, today announced a $2.9 million grant to Aeras in support of a collaboration among the three parties to support the development of vaccines against tuberculosis, HIV and malaria.

The grant, provided by the Bill & Melinda Gates Foundation, allows the three groups to work together to develop scalable methods to enable large-scale production of multiple novel chimpanzee adenovirus vector constructs.

"We are pleased to expand our partnership with Okairos focusing on novel constructs utilizing chimpanzee adenovirus for next generation TB vaccines, as well as our collaboration with the University of Oxford, both of which are central to our organizational mission," said Tom Evans, MD, Interim CEO of Aeras. "This effort to improve optimization and scale up under current good manufacturing practices could also potentially benefit our peers in HIV and malaria vaccine development."

Novel constructs to be pursued include Okairos' proprietary technology platform that uses potent chimpanzee adenovirus vectors to stimulate robust T-cell and antibody responses against selected antigens.

Dr Riccardo Cortese, Chief Executive Officer of Okairos, said: "This new collaboration will enable us to advance our promising technology platform. By continuing to work with Aeras and Oxford, partners with proven expertise in vaccines development, we ultimately aim to deliver novel vaccines to developing countries where there is great need."

Aeras and Oxford both bring to the collaboration considerable expertise in vaccine development and manufacturing, with Oxford currently developing multiple vaccines, including vaccines against HIV, malaria and TB in clinical trials in the UK and Africa, and Aeras focusing primarily on tuberculosis vaccine research and development.

"Chimpanzee adenovirus-based vaccines have recently been shown to safely induce exceptionally potent cellular immunity in adults, children and infants, and are in clinical trials involving over 1,000 vaccinees in seven countries," commented Adrian Hill, Director of the Jenner Institute at Oxford University. "The diseases targeted, including malaria, HIV/AIDS and tuberculosis, are the greatest infectious killers of our time so this investment in manufacturing technology is very timely."


'/>"/>

Contact: Annmarie Leadman
aleadman@aeras.org
240-599-3018
Aeras
Source:Eurekalert

Related medicine news :

1. Detecting malaria early to save lives: New optical technique promises rapid and accurate diagnosis
2. New process would make anti-malarial drug less costly
3. UCI researchers create mosquitoes incapable of transmitting malaria
4. The math of malaria
5. Novel anti-malarial drug target identified
6. New research reveals extent of poor-quality antimalarial medicines in South American countries
7. BioMed Central presents Challenges in Malaria Research: Progress Towards Elimination
8. Novel technique demonstrates interactions between malaria parasite and HIV
9. Meddling with male malaria mosquito mating plug to control an epidemic
10. Protein impedes microcirculation of malaria-infected red blood cells
11. New opportunity for rapid treatment of malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... The Radiology Business ... has begun to serve as its new executive director. Mr. Still was selected through ... Committee. , “Bob, as he is known to our members, has been a ...
(Date:3/28/2017)... , ... March 28, 2017 , ... With less than ... acne, access to quality care can be limited while the desire to conquer breakouts ... customized prescription acne care for every customer online, today released its inaugural survey on ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... patients desire to achieve the “perfect smile.” The National Association of Dental Laboratories ... as what dentists should be aware of when utilizing dental laboratories and technicians ...
(Date:3/28/2017)... ... March 28, 2017 , ... With expansion and efficiency in mind, Patten Seed ... The seed processing plant opened in Marshallville in 2006, and a bagging and shipping ... opportunity for transition of Patten Seed operations to the Middle Georgia location from their ...
(Date:3/28/2017)... ... ... that reveals the mystery of Kevin’s purpose. “A Prophets Bones” is the creation of published ... him that he had neglected to do, but this was from God and there was ... would have felt themselves to be special and better than others due to the fact ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Summary This report provides all the ... partnering interests and activities since 2010. Description The Partnering ... into the partnering activity of one of the world,s leading ... prepared upon purchase to ensure inclusion of the most up ... will be delivered in PDF format within 1 working day ...
(Date:3/27/2017)... 27, 2017  Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" ... offer shares of common stock in an underwritten public ... with the Securities and Exchange Commission (the "SEC"). The ... there can be no assurance as to whether or ... the actual size or terms of the offering. Cryoport ...
(Date:3/27/2017)... Calif. , March 27, 2017  Sanderling ... acquired by Ethicon, a division of Johnson & ... System for the treatment of gastro-esophageal reflux disease ... sphincter augmentation (MSA) technology and the procedure is ... centers. Torax Medical was founded by ...
Breaking Medicine Technology: